

REMARKS

Claims 1-5, 7-23, 25-27, 29-32, 34-44, 64 and 65 are present in this application and have been subjected to restriction under 35 USC §§121 and 372 as follows:

- I. Claims 1-4, 8-15, 20-23, 25-27, 29-32 and 43, drawn to polynucleotide, chimeric gene, vector, transformed cell, method of obtaining transgenic plant, and method of controlling growth of weeds;
- II. Claims 5 and 7, drawn to glutathione transferase (GST) subunit polypeptide and chimeric polypeptide;
- III. Claim 16, drawn to transformed cell;
- IV. Claims 17-19, drawn to a method for production of a polypeptide;
- V. Claims 34-36 and 44, drawn to a method of identifying compounds capable of being metabolized by GST and identified compounds;
- VI. Claim 37, drawn to an antibody;
- VII. Claim 38, drawn to a nucleic acid probe;
- VIII. Claims 39-41 and 65, drawn to a method of identifying compounds that induce GST expression;
- IX. Claim 42, drawn to a method of determining the GST level in a sample using an antibody;
- X. Claim 64, drawn to a method of determining the GST level in a sample using a nucleic acid probe.

In support of the present restriction requirement, the Examiner has alleged that the inventions of Groups I-X are not linked by a special technical feature, nor do they relate to a single general inventive concept.

The Examiner has further required that applicants elect one nucleic acid sequence and one encoded amino acid sequence to be examined in conjunction with the elected group of claims. The Examiner has alleged that each nucleotide sequence is presumed to represent an

independent and distinct invention, and that the examination of ten sequences would burden PTO resources.

In order to be fully responsive to the Examiner's requirement for restriction, Applicants elect, with traverse, the subject matter of Group I, Claims 1-4, 8-15, 20-23, 25-27, 29-32 and 43 and the nucleotide and amino acid sequences of SEQ ID NOS.: 1 and 2, respectively. However, the requirement for restriction is respectfully traversed in that the subject matter of the claims is related and this would not require an undue search burden.

Withdrawal of the requirement for restriction and favorable consideration and allowance of all pending claims is earnestly solicited.

Respectfully submitted,



Louis S. Sorell

Patent Office Reg. No. 32,439

Janet M. MacLeod

Patent Office Reg. No. 35,263

Attorneys for Applicants  
(212) 408-2597

Baker Botts, LLP  
30 Rockefeller Plaza  
44th Floor  
New York, NY 10112